GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kaken Pharmaceutical Co Ltd (TSE:4521) » Definitions » Gross-Profit-to-Asset %

Kaken Pharmaceutical Co (TSE:4521) Gross-Profit-to-Asset % : 23.86% (As of Dec. 2023)


View and export this data going back to 1961. Start your Free Trial

What is Kaken Pharmaceutical Co Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Kaken Pharmaceutical Co's annualized Gross Profit for the quarter that ended in Dec. 2023 was 円40,560 Mil. Kaken Pharmaceutical Co's average Total Assets over the quarter that ended in Dec. 2023 was 円169,994 Mil. Therefore, Kaken Pharmaceutical Co's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 23.86%.


Kaken Pharmaceutical Co Gross-Profit-to-Asset % Historical Data

The historical data trend for Kaken Pharmaceutical Co's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kaken Pharmaceutical Co Gross-Profit-to-Asset % Chart

Kaken Pharmaceutical Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Gross-Profit-to-Asset %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 32.17 25.47 25.31 23.86 22.81

Kaken Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.53 24.12 22.82 23.86 20.42

Competitive Comparison of Kaken Pharmaceutical Co's Gross-Profit-to-Asset %

For the Drug Manufacturers - Specialty & Generic subindustry, Kaken Pharmaceutical Co's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kaken Pharmaceutical Co's Gross-Profit-to-Asset % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kaken Pharmaceutical Co's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Kaken Pharmaceutical Co's Gross-Profit-to-Asset % falls into.



Kaken Pharmaceutical Co Gross-Profit-to-Asset % Calculation

Kaken Pharmaceutical Co's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Mar. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Mar. 2024 )/( (Total Assets (A: Mar. 2023 )+Total Assets (A: Mar. 2024 ))/ count )
=38539/( (166328+171623)/ 2 )
=38539/168975.5
=22.81 %

Kaken Pharmaceutical Co's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=40560/( (171651+168337)/ 2 )
=40560/169994
=23.86 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Kaken Pharmaceutical Co Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Kaken Pharmaceutical Co's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Kaken Pharmaceutical Co (TSE:4521) Business Description

Traded in Other Exchanges
Address
28-8, Honkomagome 2-chome, Bunkyo-ku, Tokyo, JPN, 1138650
Kaken Pharmaceutical Co is a specialty and generic drug manufacturing company. The company organizes its segments between pharmaceutical and real estate activities. The pharmaceutical segment consists of pharmaceutical drugs, medical devices, and agrochemicals. In the real estate segment, the majority of revenue is generated through commercial facility rental fees. Sales in Japan constitute more than 90% of revenue. Kaken considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Kaken Pharmaceutical Co (TSE:4521) Headlines

No Headlines